AI assistant
IO Biotech, Inc. — Director's Dealing 2021
Nov 5, 2021
34883_dirs_2021-11-04_e08b8492-51cd-45d1-a1a4-fe2fe26f9f3f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: IO Biotech, Inc. (IOBT)
CIK: 0001865494
Period of Report: 2021-11-04
Reporting Person: Ehrnrooth Eva (N/A)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants (Right to Buy) | $16.86 | Common Stock (9802) | Direct | ||
| Warrants (Right to Buy) | $12.64 | Common Stock (56374) | Direct | ||
| Warrants (Right to Buy) | $19.62 | Common Stock (5124) | Direct | ||
| Warrants (Right to Buy) | $12.64 | Common Stock (47425) | Direct | ||
| Warrants (Right to Buy) | $12.64 | Common Stock (183171) | Direct |
Footnotes
F1: 1 These Warrants vest in 25% annual increments starting on December 31, 2018, subject to the reporting person's continued service through the applicable vesting date.
F2: Warrants expire in annual increments on the fifth anniversary of the vesting date.
F3: These Warrants vest in 1/48 monthly increments after the May 27, 2021 vesting commencement date, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause or by the reporting person within 24 months of a change of control.
F4: These Warrants vest in 1/48 monthly increments after October 15, 2021 vesting commencement date, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause or by the reporting person within 24 months of a change of control.